Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / VTRS - Viatris down on late-stage trial setback for eye disorder therapy

VTRS - Viatris down on late-stage trial setback for eye disorder therapy

July, 18 2025 07:52 AM Viatris Inc.

2025-07-18 07:52:53 ET

More on Viatris

Viatris: A Contrarian Bet With Virtually No Downside
Viatris: The Problem With The Business Model
Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
ViiV expands license to produce generic Apretude in low-income countries
J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug

For further details see:

Viatris down on late-stage trial setback for eye disorder therapy

Stock Information

Company Name:	Viatris Inc.
Stock Symbol:	VTRS
Market:	NASDAQ
Website:	viatris.com

VTRS VTRS Quote VTRS Short VTRS News VTRS Articles VTRS Message Board

Get VTRS Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.